Molecular target inhibitors have been regularly approved by Food and Drug Administration
(FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and …

The inhibition of the mitogen-activated protein kinases signalling pathway through combined
use of BRAF and MEK inhibitors (BRAFi+ MEKi) represents an established therapeutic …

Introduction Several kinase inhibitors (KI) bear the potential to act as radiosensitizers. Little
is known of the radiosensitizing effects of a wide range of other KI like palbociclib, which is …

Background Combining stereotactic radiosurgery (SRS) and active systemic therapies (STs)
achieved favourable survival outcomes in patients with melanoma brain metastases (MBMs) …

CC-115 is a dual inhibitor of the mechanistic target of rapamycin (mTOR) kinase and the
DNA-dependent protein kinase (DNA-PK) that is currently being studied in phase I/II clinical …

(1) Kinase inhibitors (KI) targeting components of the DNA damage repair pathway are a
promising new type of drug. Combining them with ionizing radiation therapy (IR), which is …

Background PARP inhibitors niraparib and talazoparib are FDA approved for special cases
of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer …

Opinion statement With greater understanding of underlying biology and development of
effective BRAF-targeted therapy and immunotherapy, along with remarkable advances in …

Background During these last years, new agents have dramatically improved the survival of
the metastatic patients. Oligometastases represent a continuous field of interest in which the …

Purpose Despite new treatment options, melanoma continues to have an unfavorable
prognosis. DNA damage response (DDR) inhibitors are a promising drug class, especially in …